![EMERGING DRUGS AND TARGETS FOR ALZHEIMER'S DISEASE: VOLUME 1: BETA-AMYLOID](https://d3525k1ryd2155.cloudfront.net/f/631/730/9781849730631.IN.0.m.jpg)
Stock Photo: Cover May Be Different
EMERGING DRUGS AND TARGETS FOR ALZHEIMER'S DISEASE: VOLUME 1: BETA-AMYLOID Hardcover - 2010
by ANA MARTINEZ
- New
Description
New
NZ$71.43
NZ$8.32
Shipping to USA
Standard delivery: 7 to 14 days
More Shipping Options
Standard delivery: 7 to 14 days
Ships from Students Textbooks (India)
Details
- Title EMERGING DRUGS AND TARGETS FOR ALZHEIMER'S DISEASE: VOLUME 1: BETA-AMYLOID
- Author ANA MARTINEZ
- Binding Hardcover
- Edition Us Edition
- Condition New
- Pages 342
- Volumes 1
- Language ENG
- Publisher Royal Society of Chemistry
- Date 2010-05-07
- Features Bibliography, Index, Table of Contents
- Bookseller's Inventory # BIBR-1662
- ISBN 9781849730631 / 1849730636
- Weight 1.4 lbs (0.64 kg)
- Dimensions 9.2 x 6.2 x 1 in (23.37 x 15.75 x 2.54 cm)
- Dewey Decimal Code 616.831
About Students Textbooks India
Specializing in: International Edition., Textbooks
Biblio member since 2009
Selling textbooks, International editions and reference books online from last 5 Years.
30 day return guarantee, with full refund including shipping costs for up to 30 days after delivery if an item arrives misdescribed or damaged. Return address: Students_Textbooks 12 phankha road Jankpuri New Delhi 110036 India
From the rear cover
Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism will be an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.